RELAPSED/REFRACTORY MULTIPLE MYELOMA

This early-stage study tests a combination of two types of immune-based drugs (bispecific antibodies and a checkpoint inhibitor) in people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find safe doses and understand side effects.…

This early-stage trial tests an experimental drug called etentamig combined with standard treatments for multiple myeloma, a type of blood cancer. About 320 adults whose cancer has returned or not responded to prior therapy will participate. The main goal is to find the safest do…

This study tests a new way to give the drug isatuximab under the skin (instead of through a vein) for people with multiple myeloma that has come back or stopped responding to treatment. About 118 adults who have already tried 1 to 3 other treatments will receive isatuximab along …

This study tests whether adding a drug called cevostamab after standard CAR T cell therapy can help people with relapsed or refractory multiple myeloma achieve deeper, longer-lasting remission. About 30 adults who have already received CAR T cells will receive cevostamab infusion…

This study follows about 150 people who have already received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to track any long-term side effects for up to 15 years after treatment. No new treatments are given—just regular check-ups to monitor safety…